Bio-Rad Laboratories (BIO) has been under pressure recently, with the stock showing negative returns over the past week, month and past 3 months, as well as over 1 year and multi year periods. At the ...

Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...

Bio-Rad reported a year-on-year decline in revenue of 1.5% at constant currency, primarily due to weak equipment sales in life sciences due to low demand from the academic research market. Management ...

Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...

Background: Obesity has become a widespread metabolic disorder, marked by its escalating global prevalence. Puerarin, extracted from Pueraria lobata, one of the traditional homologies of medicine and ...

No audio available for this content. On Jan. 16, 2025, as part of the OPUS User Forum, the National Geodetic Survey (NGS) Northeast Regional Geodetic Advisor, Dan Martin, gave a webinar titled “Why ...

Bio-Rad Laboratories, a Bay Area biotech giant best known for its diagnostic and research products, is laying off 5% of its staff — including more than 100 workers from its headquarters in Hercules.